Targeted Oncology

SEP 12, 2026 · JOURNAL ARTICLE

Management of Adverse Events Associated with MET TKIs in Patients with Advanced NSCLC: A Podcast Discussion

Targeted Oncology

MET exon 14 (METex14) skipping is observed in approximately 3–4% of patients with non-small-cell lung cancer (NSCLC). These patients are typically older and may or may not have a h

AUG 7, 2026 · REVIEW

Impact of PSA Nadir on Outcomes in Metastatic Hormone-Sensitive Prostate Cancer: A Systematic Review and Reconstructed Individual Patient Data Meta-analysis

Targeted Oncology

Reconstructed IPD meta-analysis of 1638 patients shows PSA nadir ≤0.2 associated with substantial OS and PFS improvements (HR 0.27 and 0.19 respectively, both p<0.0001), providing robust evidence for PSA nadir as a prognostic marker in mHSPC.